Inactive Instrument

Intercept Pharmaceuticals, Inc.

Equities

ICPT

US45845P1084

Biotechnology & Medical Research

INTERCEPT PHARMACEUTICALS, INC. : Other Events (form 8-K)

January 17, 2020 at 06:33 pm IST

lack 1pt solid; font-size: 1pt">

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Latest news about Intercept Pharmaceuticals, Inc.

Intercept Presents New Sub-Analyses of Phase 3 Poise Data Showcasing the Effect of Oca on Key Liver Biomarkers in Patients with PBC at EASL Congress 2024	04/06	CI
Intercept Pharmaceuticals, Inc. Presents New Sub-Analyses of Phase 3 POISE Data Showcasing the Effect of OCA on Key Liver Biomarkers and Fibrosis in Patients with PBC at Digestive Disease Week 2024	20/05	CI
Intercept Pharmaceuticals, Inc. Presents New Data Demonstrating the Impact of OCA-Bezafibrate Combination Therapy on Alp and Metabolic Outcomes After Six Months of Treatment At Digestive Disease Week®? 2024	18/05	CI
North American Morning Briefing : Caution Dominates Ahead of CPI Print	14/11	DJ
Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage At AASLD the Liver Meeting® 2023	13/11	CI
Intercept Pharmaceuticals, Inc. Announces New Findings from Long-Term Extension of Landmark POISE Trial in PBC Showing Importance of Biomarkers Beyond ALP at AASLD the Liver Meeting® 2023	10/11	CI
Intercept Pharmaceuticals, Inc.(NasdaqGS:ICPT) dropped from NASDAQ Composite Index	08/11	CI
Intercept Pharmaceuticals, Inc.(NasdaqGS:ICPT) dropped from S&P TMI Index	08/11	CI
Intercept Pharmaceuticals, Inc.(NasdaqGS:ICPT) dropped from S&P Global BMI Index	08/11	CI
Intercept Pharmaceuticals, Inc.(NasdaqGS:ICPT) dropped from S&P Biotechnology Select Industry Index	08/11	CI
Alfasigma S.p.A. completed the acquisition of Intercept Pharmaceuticals, Inc..	08/11	CI
North American Morning Briefing : Higher Bond -2-	07/11	DJ
Intercept Pharmaceuticals, Inc.(NasdaqGS:ICPT) dropped from NASDAQ Biotechnology Index	07/11	CI
Intercept Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	07/11	CI
Persephone Biosciences Appoints Daniel Bradbury as Chair of the Board of Directors	23/23/23	CI
North American Morning Briefing : Rising Oil -2-	28/23/28	DJ
UBS Raises Intercept Pharmaceuticals Price Target to $19 From $12, Maintains Neutral Rating	27/23/27	MT
HC Wainwright Downgrades Intercept Pharmaceuticals to Neutral From Buy, Price Target is $19	27/23/27	MT
Canaccord Genuity Downgrades Intercept Pharmaceuticals to Hold From Buy, Trims Price Target to $19 From $20	27/23/27	MT
RBC Raises Price Target on Intercept Pharmaceuticals to $19 From $12 on Deal to Be Bought by Alfasigma; Sector Perform Kept	27/23/27	MT
B. Riley Downgrades Intercept Pharmaceuticals to Neutral From Buy After Announced Sale to Alfasigma, Lifts PT to $19 From $15	27/23/27	MT
Sector Update: Health Care Stocks Lower Late Tuesday Afternoon	27/23/27	MT
Sector Update: Health Care Stocks Declining in Afternoon Trading	26/23/26	MT
Intercept Pharmaceuticals Agrees to be Acquired by Alfasigma for $19 Per Share; Stock Soars Pre-Bell	26/23/26	MT
Italy's Alfasigma to buy drugmaker Intercept for nearly $800 mln	26/23/26	RE

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+20.31%	126B
REGENERON PHARMACEUTICALS, INC.	+22.90%	118B
ARGENX SE	+23.26%	27.87B
BIONTECH SE	-18.65%	20.95B
GENMAB A/S	-15.13%	16.92B
BEIGENE, LTD.	-13.69%	16.18B
NEUROCRINE BIOSCIENCES, INC.	+10.31%	14.84B
WUXI APPTEC CO., LTD.	-46.10%	14.79B
SAREPTA THERAPEUTICS, INC.	+51.60%	14.08B

1st Jan change

Capi.

VERTEX PHARMACEUTICALS INCORPORATED